Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS

NCT07227779 is registered in ClinicalTrials.gov with David Boulware as lead sponsor.

NCT NCT07227779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS
Lead sponsor
David Boulware
Phase
Phase 2
Overall status
Recruiting
Start date
July 28, 2026
Completion date
September 30, 2030
Enrollment
312 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, meningitis, tb - tuberculosis, tuberculous meningitis